IL160358A0 - Human antibodies specific for interleukin 15 (il-15) - Google Patents

Human antibodies specific for interleukin 15 (il-15)

Info

Publication number
IL160358A0
IL160358A0 IL16035802A IL16035802A IL160358A0 IL 160358 A0 IL160358 A0 IL 160358A0 IL 16035802 A IL16035802 A IL 16035802A IL 16035802 A IL16035802 A IL 16035802A IL 160358 A0 IL160358 A0 IL 160358A0
Authority
IL
Israel
Prior art keywords
human
human antibodies
antibodies
interleukin
antibodies specific
Prior art date
Application number
IL16035802A
Other languages
English (en)
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Publication of IL160358A0 publication Critical patent/IL160358A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16035802A 2001-08-23 2002-08-23 Human antibodies specific for interleukin 15 (il-15) IL160358A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31473101P 2001-08-23 2001-08-23
PCT/US2002/026769 WO2003017935A2 (en) 2001-08-23 2002-08-23 Human antibodies specific for interleukin 15 (il-15)

Publications (1)

Publication Number Publication Date
IL160358A0 true IL160358A0 (en) 2004-07-25

Family

ID=23221192

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16035802A IL160358A0 (en) 2001-08-23 2002-08-23 Human antibodies specific for interleukin 15 (il-15)
IL160358A IL160358A (en) 2001-08-23 2004-02-12 Isolated human monoclonal antibodies specific for interleukin 15 (il-15)

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160358A IL160358A (en) 2001-08-23 2004-02-12 Isolated human monoclonal antibodies specific for interleukin 15 (il-15)

Country Status (25)

Country Link
US (1) US7153507B2 (zh)
EP (1) EP1425389B1 (zh)
JP (2) JP4359503B2 (zh)
KR (1) KR100911951B1 (zh)
CN (1) CN100557018C (zh)
AT (1) ATE531390T1 (zh)
AU (1) AU2002332628B2 (zh)
BR (1) BR0212136A (zh)
CA (1) CA2456648C (zh)
CY (1) CY1112447T1 (zh)
DK (1) DK1425389T3 (zh)
EA (1) EA014802B1 (zh)
ES (1) ES2375271T3 (zh)
HK (1) HK1066828A1 (zh)
HU (1) HU229776B1 (zh)
IL (2) IL160358A0 (zh)
MX (1) MXPA04001486A (zh)
NO (1) NO333152B1 (zh)
NZ (1) NZ531211A (zh)
PL (1) PL217752B1 (zh)
PT (1) PT1425389E (zh)
RS (1) RS51829B (zh)
SI (1) SI1425389T1 (zh)
WO (1) WO2003017935A2 (zh)
ZA (1) ZA200401144B (zh)

Families Citing this family (269)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US7329405B2 (en) 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
RS51829B (sr) 2001-08-23 2012-02-29 Genmab A/S. Ljudska antitela specifična za interleukin 15 (il-15)
GB0208817D0 (en) * 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
EA015897B1 (ru) * 2003-02-26 2011-12-30 Генмаб А/С Применение человеческого моноклонального антитела к ил-15 в составе композиции и лекарственного препарата (варианты), композиция и лекарственный препарат, его включающие
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
US20050123542A1 (en) * 2003-11-06 2005-06-09 Genmab A/S Methods for treating disorders involving monocytes
AU2005299716B2 (en) * 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
RU2007126553A (ru) * 2004-12-13 2009-01-20 Цитос Биотехнологи Аг (Ch) Упорядоченные ряды антигенов ил-15 и их применение
CA2903138A1 (en) 2005-05-16 2006-11-23 Abbvie Biotechnology Ltd. Use of tnfa inhibitor for treatment of erosive polyarthritis
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
EP2468776A3 (en) 2007-02-09 2012-11-14 Genentech, Inc. Anti-Robo4 antibodies and uses therefor
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
JP5570989B2 (ja) * 2007-08-31 2014-08-13 アムジエン・インコーポレーテツド 固体タンパク質製剤
JP5963341B2 (ja) * 2007-09-14 2016-08-10 アムジエン・インコーポレーテツド 均質な抗体集団
CA2701032C (en) 2007-09-27 2021-01-26 Amgen Inc. Pharmaceutical formulations
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
EP2271671A2 (en) * 2008-03-24 2011-01-12 Abbott Biotechnology Ltd. Tnf-alpha inhibitors for treating bone loss
CU23716A1 (es) 2008-09-30 2011-10-05 Ct Ingenieria Genetica Biotech Péptido antagonista de la actividad de la interleucina-15
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
DK2473522T3 (en) 2009-09-02 2016-11-28 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
AU2010310457B2 (en) 2009-10-23 2015-07-02 Amgen Inc. Vial adapter and system
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
WO2011084750A1 (en) 2009-12-21 2011-07-14 Genentech, Inc. Antibody formulation
RS54291B2 (sr) 2010-06-07 2023-12-29 Amgen Inc Uređaj za isporuku lekova
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
BR112012031727B1 (pt) 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
EP2625197B1 (en) 2010-10-05 2016-06-29 Genentech, Inc. Mutant smoothened and methods of using the same
MX341790B (es) 2011-03-31 2016-09-02 Amgen Inc Adaptador de viales y sistema.
PL2699293T3 (pl) 2011-04-20 2019-08-30 Amgen Inc. Urządzenie do wstrzykiwania automatycznego
CN102250243B (zh) * 2011-07-01 2013-08-28 华绍炳 抗白细胞介素-15抗体
CN107843730B (zh) * 2011-07-18 2021-08-20 Iba生命科学股份有限公司 使靶细胞可逆染色的方法
DK3045189T3 (en) 2011-10-14 2018-06-18 Amgen Inc Injector and mounting method
ES2780395T3 (es) 2012-11-21 2020-08-25 Amgen Inc Dispositivo de administración de fármacos
EP2958941B1 (en) 2013-02-20 2019-04-10 Innate Pharma A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
BR112015022484A2 (pt) 2013-03-13 2017-07-18 Genentech Inc formulações com oxidação reduzida
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
CA3135558A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Prevention of protein oxidation in a composition
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
KR102127085B1 (ko) 2013-03-13 2020-06-26 제넨테크, 인크. 항체 제제
US10092703B2 (en) 2013-03-15 2018-10-09 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
JP6768501B2 (ja) 2013-03-15 2020-10-14 アムゲン・インコーポレーテッド 薬物カセット、自動注入機、および自動注入機システム
RU2718986C2 (ru) 2013-03-15 2020-04-15 Дженентек, Инк. Композиции клеточных культур с антиоксидантами и способы получения полипептидов
BR112015024282B1 (pt) 2013-03-22 2022-05-17 Amgen Inc Injetor e método de montagem do injetor
SG11201602283UA (en) 2013-09-27 2016-04-28 Genentech Inc Anti-pdl1 antibody formulations
CN105873626A (zh) 2013-10-24 2016-08-17 美国安进公司 注射器和组装方法
US10758683B2 (en) 2013-10-24 2020-09-01 Amgen Inc. Drug delivery system with temperature-sensitive control
US20150210772A1 (en) 2013-12-17 2015-07-30 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
EP3083687A2 (en) 2013-12-17 2016-10-26 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
HUE047699T2 (hu) 2013-12-17 2020-05-28 Hoffmann La Roche Eljárások rákbetegségek kezelésére PD-1-tengelyhez kötõdõ antagonisták és taxánok alkalmazásával
AU2015214264B2 (en) 2014-02-04 2018-12-20 Curis, Inc. Mutant Smoothened and methods of using the same
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
JP6640113B2 (ja) 2014-05-07 2020-02-05 アムジエン・インコーポレーテツド 衝撃低減要素を有する自動注入器
CA2949846C (en) 2014-06-03 2023-09-05 Amgen Inc. Devices and methods for assisting a user of a drug delivery device
EP2963057A1 (en) 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
EP3193932B1 (en) 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Antibody formulations
MX2021014323A (es) 2014-10-14 2023-02-02 Amgen Inc Dispositivo de inyección de fármaco con indicadores visuales y audibles.
AU2015335743B2 (en) 2014-10-23 2020-12-24 Amgen Inc. Reducing viscosity of pharmaceutical formulations
US20160166685A1 (en) 2014-11-17 2016-06-16 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
WO2016100781A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with proximity sensor
JP2018512597A (ja) 2015-02-04 2018-05-17 ジェネンテック， インコーポレイテッド 突然変異体スムースンド及びその使用方法
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
US11806509B2 (en) 2015-02-27 2023-11-07 Amgen Inc. Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
KR20180018538A (ko) 2015-06-17 2018-02-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
PT3334747T (pt) 2015-08-13 2023-12-12 Amgen Inc Formulação de gonadotrofina líquida estável
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
KR20180098625A (ko) 2015-12-30 2018-09-04 제넨테크, 인크. 분해가 감소된 폴리소르베이트를 갖는 제형
AU2016381694A1 (en) 2015-12-30 2018-07-05 Genentech, Inc. Use of tryptophan derivatives for protein formulations
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
CA3006529A1 (en) 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
AU2017213826A1 (en) 2016-02-04 2018-08-23 Curis, Inc. Mutant smoothened and methods of using the same
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
EP4112641A1 (en) 2016-03-15 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
JP7309363B2 (ja) 2016-05-13 2023-07-18 アムジエン・インコーポレーテツド バイアル・スリーブ組立体
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US20180002417A1 (en) * 2016-06-15 2018-01-04 Celimmune Llc Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
EP3497129A1 (en) 2016-08-08 2019-06-19 H. Hoffnabb-La Roche Ag Therapeutic and diagnostic methods for cancer
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
US11459401B2 (en) 2016-10-06 2022-10-04 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
JP6884858B2 (ja) * 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
UA126284C2 (uk) * 2016-12-21 2022-09-14 Сефалон, Інк. Антитіла, які специфічно зв'язуються з людським il-15, та їхнє застосування
US11168147B2 (en) 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
JP2020503976A (ja) 2017-01-17 2020-02-06 アムジエン・インコーポレーテツド 注入デバイスならびに関連する使用および組立方法
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
JP7280189B2 (ja) 2017-02-17 2023-05-23 アムジエン・インコーポレーテツド 薬物送達装置用の挿入機構
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
WO2018165499A1 (en) 2017-03-09 2018-09-13 Amgen Inc. Insertion mechanism for drug delivery device
CA3052676A1 (en) 2017-03-28 2018-10-04 Amgen Inc. Plunger rod and syringe assembly system and method
US11278505B2 (en) 2017-04-24 2022-03-22 University Of Massachusetts Diagnosis and treatment of vitiligo
US20200048367A1 (en) 2017-04-28 2020-02-13 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
CN110709121B (zh) 2017-06-08 2022-06-24 安进公司 扭矩驱动式药物递送装置
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MA49447A (fr) 2017-06-22 2020-04-29 Amgen Inc Réduction des impacts/chocs d'activation d'un dispositif
EP3641861A1 (en) 2017-06-23 2020-04-29 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM
MA49626A (fr) 2017-07-21 2020-05-27 Amgen Inc Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
EP3662288B1 (en) 2017-08-01 2024-02-28 Amgen Inc. Systems and methods for performing a real-time glycan assay of a sample
MA49757A (fr) 2017-08-01 2020-06-10 Amgen Inc Systèmes et procédés de préparation en temps réel d'un échantillon de polypeptide pour analyse par spectrométrie de masse
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
IL272636B1 (en) 2017-10-06 2024-06-01 Amgen Inc Drug delivery device with combination assembly and related assembly method
EP3694578A1 (en) 2017-10-09 2020-08-19 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
US11826480B2 (en) 2017-11-03 2023-11-28 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
CA3079197A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
US20200338271A1 (en) 2017-11-06 2020-10-29 Amgen Inc. Fill-finish assemblies and related methods
CN116832271A (zh) 2017-11-10 2023-10-03 安进公司 用于药物递送装置的柱塞
JP2021503311A (ja) 2017-11-16 2021-02-12 アムジエン・インコーポレーテツド 失速及び終点検出を有するオートインジェクタ
CA3079540A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
EP3740264A1 (en) 2018-01-17 2020-11-25 Amgen Inc. Drug delivery mechanism
WO2019173026A1 (en) 2018-03-07 2019-09-12 Amgen Inc. Controlled dispense syringe
EP3762067A1 (en) 2018-03-09 2021-01-13 Amgen Inc. Backflow prevention mechanism for drug delivery device
US20210255075A1 (en) 2018-03-13 2021-08-19 Amgen Inc. Sequential digestion of polypeptides for mass spectrometric analysis
US20210041453A1 (en) 2018-03-13 2021-02-11 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
US11499922B2 (en) 2018-03-30 2022-11-15 Amgen Inc. Camera-based drug container inspection
US11583633B2 (en) 2018-04-03 2023-02-21 Amgen Inc. Systems and methods for delayed drug delivery
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
US20200030443A1 (en) 2018-06-23 2020-01-30 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
WO2020018789A1 (en) 2018-07-18 2020-01-23 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
CN112469454B (zh) 2018-07-24 2024-01-26 安进公司 用于施用药物的输送装置
EP3826699A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
EP3829692A1 (en) 2018-07-31 2021-06-09 Amgen Inc. Fluid path assembly for a drug delivery device
WO2020033485A1 (en) 2018-08-08 2020-02-13 Genentech, Inc. Use of tryptophan derivatives and l-methionine for protein formulation
JP2021533844A (ja) 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド 薬物送達デバイスのための作動機構
JP7475336B2 (ja) 2018-09-21 2024-04-26 ジェネンテック， インコーポレイテッド トリプルネガティブ乳癌のための診断方法
MA53724A (fr) 2018-09-24 2021-12-29 Amgen Inc Systèmes et procédés de dosage interventionnel
WO2020068476A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
CN112805048B (zh) 2018-10-02 2023-09-22 安进公司 具有内部力传递的用于药物递送的注射系统
AR116607A1 (es) 2018-10-05 2021-05-26 Amgen Inc Dispositivo de administración de fármacos con indicador de dosis
SG11202101824VA (en) 2018-10-15 2021-03-30 Amgen Inc Platform assembly process for drug delivery device
AR116704A1 (es) 2018-10-15 2021-06-02 Amgen Inc Dispositivo de administración de fármacos con mecanismo de amortiguación
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
MA54048A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
WO2020124008A1 (en) 2018-12-14 2020-06-18 Amgen Inc. System suitability method for use with protein concentration determination by slope
JP7483723B2 (ja) 2019-01-24 2024-05-15 アムジエン・インコーポレーテツド 背圧検知による薬剤送達のシステム及び方法
US11534547B2 (en) 2019-01-24 2022-12-27 Amgen Inc. Drug delivery systems and methods with pressure sensitive control
AU2020221446A1 (en) 2019-02-12 2021-07-01 Amgen Inc. Continuous dosing systems and approaches
WO2020167910A1 (en) 2019-02-12 2020-08-20 Amgen Inc. Systems and approaches for drug delivery device reconstitution
US20220062543A1 (en) 2019-02-12 2022-03-03 Amgen Inc. Continuous dosing systems and approaches
WO2020167541A1 (en) 2019-02-12 2020-08-20 Amgen Inc. Dosing systems and approaches
US20200254173A1 (en) 2019-02-12 2020-08-13 Amgen Inc. Take-home drug delivery system
US20220096747A1 (en) 2019-02-12 2022-03-31 Amgen Inc. Continuous dosing systems and approaches
JP7483731B2 (ja) 2019-02-14 2024-05-15 アムジエン・インコーポレーテツド 試料の調製及びその試料のリアルタイムアッセイの実施のためのシステム及び方法
AU2020226619A1 (en) 2019-02-20 2021-08-05 Amgen Inc. Methods of determining protein stability
EP3935396A1 (en) 2019-03-04 2022-01-12 Amgen Inc. In vivo reversibility of high molecular weight species
CA3133459A1 (en) 2019-03-27 2020-10-01 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
WO2020210094A1 (en) 2019-04-08 2020-10-15 Amgen Inc. Automated drug delivery device and container
AU2020271035A1 (en) 2019-04-09 2021-09-09 Amgen Inc. Drug delivery device with smart grip
WO2020214492A1 (en) 2019-04-17 2020-10-22 Amgen Inc. Cassette for an autoinjector and related methods
MX2021012557A (es) 2019-04-24 2021-11-12 Amgen Inc Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
EP3958925A1 (en) 2019-04-24 2022-03-02 Amgen Inc. Injector accessories
MX2021014733A (es) 2019-06-05 2022-04-06 Amgen Inc Metodos de identificacion de atributos de proteinas terapeuticas.
JP2022536898A (ja) 2019-06-12 2022-08-22 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－１５プロドラッグおよびその使用方法
MX2021015571A (es) 2019-06-20 2022-01-24 Amgen Inc Dispositivo y metodo de administracion de farmacos habilitados para comunicacion inalambrica.
US20220362474A1 (en) 2019-07-18 2022-11-17 Amgen Inc. Drug delivery device having pressurized vessel
WO2021011717A1 (en) 2019-07-18 2021-01-21 Amgen Inc. Sealing arrangement for drug delivery device
MX2022001112A (es) 2019-08-01 2022-02-16 Amgen Inc Dispositivo de suministro de farmacos con medicion de la temperatura y metodo relacionado.
CA3148261A1 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
EP4025272A1 (en) 2019-09-03 2022-07-13 Amgen Inc. Injection device for drug delivery and packaging for the injection device
JP2022545556A (ja) 2019-09-03 2022-10-27 アムジエン・インコーポレーテツド 薬物送達用の起動可能な注入デバイス
US20220362462A1 (en) 2019-09-12 2022-11-17 Amgen Inc. Backflow Prevention Mechanism for Drug Delivery Device
US20210077645A1 (en) 2019-09-16 2021-03-18 Amgen Inc. Method for external sterilization of drug delivery device
CN114423475B (zh) 2019-09-30 2024-03-26 美国安进公司 药物递送装置和用于递送药物的方法
MX2022003802A (es) 2019-09-30 2022-04-29 Amgen Inc Dispositivo de administracion de farmacos.
JP2022549687A (ja) 2019-09-30 2022-11-28 アムジエン・インコーポレーテツド 薬物送達デバイス
CA3152549A1 (en) 2019-09-30 2021-04-08 Amgen Inc. Drug delivery device
MX2022003700A (es) 2019-09-30 2022-04-26 Amgen Inc Dispositivo de administracion de farmacos.
US11878149B2 (en) 2019-09-30 2024-01-23 Amgen Inc. Drug delivery device
EP4041347A1 (en) 2019-10-07 2022-08-17 Amgen Inc. Drug delivery device with fingerprint sensor
WO2021071831A1 (en) 2019-10-07 2021-04-15 Amgen Inc. Packages for pharmaceutical products and methods of assembly
EP4041342A1 (en) 2019-10-07 2022-08-17 Amgen Inc. Needle insertion mechanism for drug delivery device
US11660435B2 (en) 2019-10-07 2023-05-30 Amgen Inc. Light-activated ultrasonic delivery and manipulation of liquid medication from a drug reservoir
CA3152217A1 (en) 2019-10-08 2021-04-15 Amgen Inc. Temperature indicator for drug delivery device
WO2021071917A1 (en) 2019-10-08 2021-04-15 Amgen Inc. Cassette for an autoinjector and related methods
WO2021071740A1 (en) 2019-10-08 2021-04-15 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2021071886A1 (en) 2019-10-08 2021-04-15 Amgen Inc. Drug delivery device
AU2020366423A1 (en) 2019-10-18 2022-04-14 Amgen Inc. Systems and approaches for drug delivery device reconstitution
AU2020368455A1 (en) 2019-10-18 2022-04-07 Amgen Inc. Systems and approaches for drug delivery device reconstitution
EP4045108A1 (en) 2019-10-18 2022-08-24 Amgen Inc. Drug delivery device and system
US20240091440A1 (en) 2019-10-18 2024-03-21 Amgen Inc. Drug delivery device and system
EP4048346A1 (en) 2019-10-21 2022-08-31 Amgen Inc. Drug product container and drug delivery system
US20220387702A1 (en) 2019-10-24 2022-12-08 Amgen Inc. Drug delivery device
US20220378657A1 (en) 2019-10-24 2022-12-01 Amgen Inc. Systems and components for drug delivery and components for preparation of the same
EP4048345A1 (en) 2019-10-24 2022-08-31 Amgen, Inc Drug delivery device and system
MX2022004943A (es) 2019-10-24 2022-05-16 Amgen Inc Sistemas y enfoques para la administracion de farmacos.
WO2021080822A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Systems and methods for drug delivery
EP4054673A1 (en) 2019-11-07 2022-09-14 Amgen Inc. Drug delivery system and method of use
WO2021113101A1 (en) 2019-12-02 2021-06-10 Amgen Inc. Lockout mechanism for drug delivery device
US20230347075A1 (en) 2019-12-05 2023-11-02 Amgen Inc. Flow restrictor for drug delivery device
CA3165927A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
EP4090398A1 (en) 2020-01-13 2022-11-23 Amgen Inc. Needle shield removers, drug delivery devices, and related methods
MX2022010177A (es) 2020-02-24 2022-09-12 Amgen Inc Envases y sistemas para su uso durante la esterilizacion externa de dispositivos de administracion de farmacos.
AU2021237384A1 (en) 2020-03-16 2022-08-25 Amgen Inc. Drug delivery member insertion sensing assemblies, drug delivery devices, and related methods
JP2023518226A (ja) 2020-03-17 2023-04-28 アムジエン・インコーポレーテツド 制御型吐出シリンジ
US20230135301A1 (en) 2020-04-28 2023-05-04 Amgen Inc. Packaging label
WO2021236477A1 (en) 2020-05-22 2021-11-25 Amgen Inc. Storage system and method for storing and transporting medicament
CA3181820A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
US20230294868A1 (en) 2020-09-02 2023-09-21 Amgen Inc. Easy open apparatus for medicament storage carton
EP4210805A1 (en) 2020-09-09 2023-07-19 Amgen Inc. Swallowable drug delivery devices
WO2022055761A1 (en) 2020-09-11 2022-03-17 Amgen Inc. Inline uv flow device for sterilizing flow cytometry sheath fluid
TW202227470A (zh) 2020-09-18 2022-07-16 美商安進公司 處理樣本用於肽作圖分析之方法
WO2022081276A1 (en) 2020-10-12 2022-04-21 Amgen Inc. Long-term medicament storage apparatus and methods
AU2021374583A1 (en) 2020-11-04 2023-04-20 Amgen Inc. Drug delivery device assembly and accessory for drug delivery device
MX2023005061A (es) 2020-11-04 2023-05-12 Amgen Inc Ensamblaje de dispositivo de administracion de farmacos y accesorio para dispositivo de administracion de farmacos.
AU2021376245A1 (en) 2020-11-04 2023-04-13 Amgen Inc. Drug delivery device assembly and accessory for drug delivery device
MX2023005062A (es) 2020-11-04 2023-05-12 Amgen Inc Ensamblaje de dispositivo de administracion de farmacos y accesorio para dispositivo de administracion de farmacos.
JP2023549113A (ja) 2020-11-05 2023-11-22 アムジエン・インコーポレーテツド タンパク質を処理するための材料及び方法
WO2022169726A1 (en) 2021-02-03 2022-08-11 Amgen Inc. Systems and approaches for drug processing
WO2022169724A1 (en) 2021-02-03 2022-08-11 Amgen Inc. Coaxial needle adapter and guide bracket for robotic liquid handling platform
WO2022169725A1 (en) 2021-02-03 2022-08-11 Amgen Inc. High-throughput automated reconstitution of lyophilized drug product
JP2024510946A (ja) 2021-03-08 2024-03-12 アムジエン・インコーポレーテツド 中空プランジャロッドの製造プロセス
TW202241534A (zh) 2021-03-10 2022-11-01 美商安進公司 具有可移除蓋之藥物遞送裝置
US20220288324A1 (en) 2021-03-10 2022-09-15 Amgen Inc. Drug delivery device
MX2023010440A (es) 2021-03-10 2023-09-12 Amgen Inc Dispositivo de administracion de farmacos, subconjunto para dispositivo de administracion de farmacos, soporte de jeringa y metodo de ensamblado.
EP4313213A1 (en) 2021-03-25 2024-02-07 Amgen Inc. Drug delivery device
MX2023011391A (es) 2021-03-31 2023-10-09 Amgen Inc Sistema de medicion del tiempo de inyeccion basado en la deteccion de sonido para dispositivos de administracion de farmacos.
EP4327056A1 (en) 2021-04-22 2024-02-28 Amgen Inc. Methods and systems for automated syringe quality evaluation
WO2022232199A1 (en) 2021-04-28 2022-11-03 Amgen Inc. Systems for out-patient treatment of a patient, and related methods
WO2022245574A1 (en) 2021-05-17 2022-11-24 Amgen Inc. Feedback system and method for a drug product
WO2022246055A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
WO2022256199A1 (en) 2021-06-01 2022-12-08 Amgen Inc. Lyophilization system
AU2022288864A1 (en) 2021-06-08 2023-10-19 Amgen Inc. Drug delivery devices, finger-grip elements, and related methods
IL309176A (en) 2021-06-17 2024-02-01 Amgen Inc Drug delivery device with shock absorber
AR126197A1 (es) 2021-06-23 2023-09-27 Amgen Inc Jeringuillas, conjuntos y métodos de fabricación referencias a la solicitud relacionada
WO2023278125A1 (en) 2021-06-28 2023-01-05 Amgen Inc. Safety device for drug delivery system
EP4370087A1 (en) 2021-07-16 2024-05-22 Amgen Inc. Systems and approaches for drug processing single-use hardware
CA3228140A1 (en) 2021-09-29 2023-04-06 Amgen Inc. Apparatuses, systems and methods for plunger-stopper depth measurement in pre-filled syringes
WO2023059671A1 (en) 2021-10-06 2023-04-13 Amgen Inc. Impact activated retention feature for drug delivery device
AR127250A1 (es) 2021-10-06 2024-01-03 Amgen Inc Herramienta de freno activado por impacto para dispositivo de administración de fármacos
CA3232202A1 (en) 2021-10-11 2023-04-20 Amgen Inc. Characterization apparatus for drug delivery devices or subcomponents thereof
AU2022382741A1 (en) 2021-11-05 2024-04-04 Amgen Inc. Drug delivery devices, components for use within drug delivery devices
WO2023086793A1 (en) 2021-11-09 2023-05-19 Amgen Inc. Production of therapeutic proteins
AU2022396290A1 (en) 2021-11-29 2024-04-04 Amgen Inc. Plunger rod removal force method and fixture
CA3236413A1 (en) 2021-12-03 2023-06-08 Amgen Inc. Stopper placement in a syringe
WO2023172592A1 (en) 2022-03-11 2023-09-14 Amgen Inc. Adjustable depth autoinjector
WO2023196111A1 (en) 2022-04-06 2023-10-12 Amgen Inc. Packaging for drug delivery device
WO2024028448A1 (en) 2022-08-04 2024-02-08 Calypso Biotech Sa Il-15 inhibitors useful for the treatment of atopic dermatitis
WO2024040020A1 (en) 2022-08-15 2024-02-22 Absci Corporation Quantitative affinity activity specific cell enrichment
WO2024039707A1 (en) 2022-08-18 2024-02-22 Amgen Inc. Needle shield assembly for a syringe
WO2024039575A1 (en) 2022-08-18 2024-02-22 Amgen Inc. Needle shield for syringe
WO2024049793A1 (en) 2022-08-30 2024-03-07 Amgen Inc. System and method of limiting subvisible particles in a syringe
CN117209605B (zh) * 2023-11-09 2024-01-30 北京百普赛斯生物科技股份有限公司 特异性结合il-15的抗体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU633698B2 (en) * 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US5591630A (en) * 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
AU700250B2 (en) * 1995-04-02 1998-12-24 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for curing thrombocytopenia
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5660824A (en) * 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
CA2252557A1 (en) * 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center, Inc. Antagonists of interleukin-15
AU729515B2 (en) * 1996-10-17 2001-02-01 Immunomedics Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
DE69810091T2 (de) * 1997-02-21 2003-10-09 Vlaams Interuniv Inst Biotech Verwendung von interleukin-15
DE69835145T2 (de) * 1997-02-28 2007-06-14 Kirin Beer K.K. Transgene Mäuse die ein menschliches Antikörper exprimieren
GB9814892D0 (en) * 1998-07-10 1998-09-09 Kennedy Rheumatology Inst Treatment of celiac disease
WO2001002003A1 (en) * 1999-07-06 2001-01-11 Bulfone Paus Silvia Method of treating psoriasis with il-15 antagonist
RS51829B (sr) 2001-08-23 2012-02-29 Genmab A/S. Ljudska antitela specifična za interleukin 15 (il-15)

Also Published As

Publication number Publication date
PL371946A1 (en) 2005-07-11
EA014802B1 (ru) 2011-02-28
WO2003017935A3 (en) 2003-08-14
EP1425389A2 (en) 2004-06-09
MXPA04001486A (es) 2004-10-27
BR0212136A (pt) 2004-12-07
AU2002332628B2 (en) 2007-07-26
ZA200401144B (en) 2005-05-12
EP1425389B1 (en) 2011-11-02
SI1425389T1 (sl) 2012-02-29
PT1425389E (pt) 2012-02-07
JP2005503151A (ja) 2005-02-03
ATE531390T1 (de) 2011-11-15
WO2003017935A9 (en) 2003-04-10
HUP0402653A2 (hu) 2005-03-29
JP2009256354A (ja) 2009-11-05
WO2003017935A2 (en) 2003-03-06
KR20040047796A (ko) 2004-06-05
YU15104A (sh) 2006-08-17
IL160358A (en) 2010-12-30
KR100911951B1 (ko) 2009-08-13
CY1112447T1 (el) 2015-12-09
HU229776B1 (hu) 2014-07-28
NO333152B1 (no) 2013-03-18
HK1066828A1 (en) 2005-04-01
CA2456648C (en) 2011-08-16
ES2375271T3 (es) 2012-02-28
US20030138421A1 (en) 2003-07-24
CN100557018C (zh) 2009-11-04
EA200400345A1 (ru) 2004-12-30
CN1571836A (zh) 2005-01-26
NO20040752L (no) 2004-04-24
NZ531211A (en) 2007-04-27
JP4359503B2 (ja) 2009-11-04
DK1425389T3 (da) 2012-01-30
PL217752B1 (pl) 2014-08-29
HUP0402653A3 (en) 2010-01-28
US7153507B2 (en) 2006-12-26
CA2456648A1 (en) 2003-03-06
RS51829B (sr) 2012-02-29
EP1425389A4 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
IL160358A (en) Isolated human monoclonal antibodies specific for interleukin 15 (il-15)
LTPA2021514I1 (zh)
TW200500378A (en) Human antibodies specific for interleukin 15 (IL-15)
HK1082749A1 (en) Human monoclonal antibodies against interleukin 8 (il-8)
AU2003303237A8 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
HK1049015A1 (en) Human monoclonal antibodies to prostate specific membrane antigen
WO2003064606A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
MXPA05012571A (es) Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis.
WO2004043989A3 (en) Human monoclonal antibodies to heparanase
RS20050724A (en) Human antibodies specific for interleukin 15(il-15)